Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.38 |
| ▸ | GSK3A | P49840 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 7/20 | 0.35 |
| ▸ | SYK | P43405 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086934 | 0.85 | MAPK14 (0.33) | MAPK14MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL28756094 | 0.84 | ALDH1A1 (0.40) | MAPK14GSK3AMAPTSMN1; SMN2HTT | |
| SCHEMBL16106451 | 0.83 | MAPK14 (0.50) | MAPK14GSK3AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1847413 | 0.82 | MAPK14 (0.39) | MAPK14MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL15743699 | 0.80 | HTR1D (0.33) | — | |
| SCHEMBL16829471 | 0.80 | GSK3A (0.49) | MAPK14GSK3ASRCSYK | |
| SCHEMBL16829458 | 0.79 | MAPK14 (0.50) | MAPK14GSK3AHTTMEN1KMT2A | |
| SCHEMBL16829221 | 0.79 | MAPK14 (0.50) | MAPK14GSK3AMAPTTP53SMN1; SMN2 | |
| SCHEMBL16829249 | 0.79 | MAPK14 (0.50) | MAPK14GSK3AHTTMEN1KMT2A | |
| SCHEMBL1848243 | 0.78 | HPGD (0.43) | MAPK14GSK3AMAPTHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890185-B2 | Urea derivatives useful as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20160318958-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083604-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092423-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318958-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | SYK, UACA, YES1 | MAPK14 197/4885GSK3A 853/4885MAPT 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.